-
101.发明授权Transgenic non-human animals expressing human blood clotting factors and uses thereof 有权表达人凝血因子的转基因非人动物及其用途公开(公告)号：US08962912B2
公开(公告)日：2015-02-24
申请号：US13071190
申请日：2011-03-24
申请人： Maria Sasgary , Maria Schuster , Hans-Peter Schwarz , Birgit Maria Reipert , Gerhard Antoine , Hartmut Ehrlich
发明人： Maria Sasgary , Maria Schuster , Hans-Peter Schwarz , Birgit Maria Reipert , Gerhard Antoine , Hartmut Ehrlich
IPC分类号： A01K67/027 , G01N33/00 , C12N15/00 , C12N15/85 , C07K14/745 , C07K14/755 , C12N9/64
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/15 , A01K2227/105 , A01K2267/02 , A01K2267/03 , C07K14/745 , C07K14/755 , C12N9/64
摘要： The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.
摘要翻译： 本发明一般涉及表达人血液凝固因子如因子VIII，因子VII，因子IX和血管性血友病因子的非人转基因动物的开发。 本发明还提供使用所述转基因动物检测针对人血液凝固因子的免疫原性事件的方法。
-
102.发明授权Solid phase-bound elastase-binding assay for the measurement of alpha1-antitrypsin activity 有权用于测量α1-抗胰蛋白酶活性的固相结合弹性蛋白酶结合测定法公开(公告)号：US08652793B2
公开(公告)日：2014-02-18
申请号：US13455979
申请日：2012-04-25
IPC分类号： G01N33/53 , G01N33/547 , C12Q1/37
CPC分类号： G01N33/68 , G01N33/53 , G01N2333/8125 , G01N2333/966
摘要： The present invention relates to a method for the measurement of active alpha1-proteinase inhibitor (A1PI) in a sample, comprising the steps of binding elastase to a solid support, letting the A1PI contained in the sample bind to the solid phase-bound elastase, and detecting solid phase-bound A1PI with a detection reagent.
摘要翻译： 本发明涉及一种用于测量样品中活性α1-蛋白酶抑制剂（A1PI）的方法，包括以下步骤：将弹性蛋白酶与固体支持物结合，使样品中包含的A1PI与固相结合的弹性蛋白酶结合， 并用检测试剂检测固相键A1PI。
-
公开(公告)号：US08623352B2
公开(公告)日：2014-01-07
申请号：US12887424
申请日：2010-09-21
CPC分类号： A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
摘要： The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
摘要翻译： 本发明涉及具有增强或期望性质的ADAMTS13制剂。 因此，本发明提供了适用于药物给药的ADAMTS13的液体和冻干制剂。 除了其它方面，本发明还提供了治疗受试者中与VWF和/或ADAMTS13功能障碍相关的各种疾病和病症的方法。 本文还提供了包含可用于治疗各种疾病和病症的ADAMTS13制剂的试剂盒。
-
公开(公告)号：US08603830B2
公开(公告)日：2013-12-10
申请号：US13410114
申请日：2012-03-01
CPC分类号： G01N33/50 , G01N33/92 , G01N2400/00
摘要： The present invention relates to a method for the determination of polysorbate in a protein-containing sample. The method of the present invention involves the pretreatment of the sample by alkaline hydrolysis followed by colorimetric determination.
摘要翻译： 本发明涉及一种测定含蛋白质样品中的聚山梨醇酯的方法。 本发明的方法涉及通过碱水解进行样品预处理，然后进行比色测定。
-
105.发明申请METHOD FOR REDUCING THE THROMBOEMBOLIC POTENTIAL OF A PLASMA-DERIVED IMMUNOGLOBULIN COMPOSITION 有权降低等离子体衍生的免疫球蛋白组成的血栓形成潜力的方法公开(公告)号：US20130058961A1
公开(公告)日：2013-03-07
申请号：US13595967
申请日：2012-08-27
申请人： Wolfgang Teschner , Harald Arno Butterweck , Bernhard Kölbl , Lucia Hofbauer , Hans-Peter Schwarz
发明人： Wolfgang Teschner , Harald Arno Butterweck , Bernhard Kölbl , Lucia Hofbauer , Hans-Peter Schwarz
IPC分类号： A61K39/395 , A61P29/00 , A61P31/00 , A61P37/06
CPC分类号： C07K16/065
摘要： The present invention provides methods for reducing the amidolytic and anti-complement activity (ACA) content of an immunoglobulin composition through the use of cation exchange chromatography. In a specific embodiment, the invention provides methods for reducing the Factor XI and/or Factor XIa and/or ACA content of an immunoglobulin composition by collecting the leading portion of a cation exchange eluate. The present invention also provides immunoglobulin composition having reduced levels of amidolytic activity, Factor XI, and/or Factor XIa, and/or ACA content.
摘要翻译： 本发明提供了通过使用阳离子交换色谱法降低免疫球蛋白组合物的酰胺分解和抗补体活性（ACA）含量的方法。 在具体实施方案中，本发明提供通过收集阳离子交换洗脱液的前导部分来减少免疫球蛋白组合物的因子XI和/或因子XIa和/或ACA含量的方法。 本发明还提供了具有降低的酰胺分解活性水平，因子XI和/或因子XIa和/或ACA含量的免疫球蛋白组合物。
-
106.发明申请公开(公告)号：US20120135019A1
公开(公告)日：2012-05-31
申请号：US13283452
申请日：2011-10-27
申请人： Katharina Nora Steinitz , Paula Maria Wilhelmina van Helden , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
发明人： Katharina Nora Steinitz , Paula Maria Wilhelmina van Helden , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
CPC分类号： C07K14/755 , A61K38/37 , C07K2319/00 , C12P21/00 , G01N33/505 , G01N33/56977
摘要： The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
摘要翻译： 本发明涉及可用于降低针对FVIII的免疫应答或诱导对例如血友病A的患者对人FVIII的耐受性的肽。此外，该肽可用于免疫诊断目的以检测FVIII-特异性CD4 + T细胞在替代治疗期间和免疫耐受诱导治疗期间监测血友病A患者。
-
107.发明申请Transgenic Non-Human Animals Expressing Human Blood Clotting Factors and Uses Thereof 有权表达人血液凝血因子的转基因非人动物及其用途公开(公告)号：US20120082987A1
公开(公告)日：2012-04-05
申请号：US13071190
申请日：2011-03-24
申请人： Maria Sasgary , Maria Schuster , Hans-Peter Schwarz , Birgit Reipert , Gerhard Antoine , Hartmut Ehrlich
发明人： Maria Sasgary , Maria Schuster , Hans-Peter Schwarz , Birgit Reipert , Gerhard Antoine , Hartmut Ehrlich
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/15 , A01K2227/105 , A01K2267/02 , A01K2267/03 , C07K14/745 , C07K14/755 , C12N9/64
摘要： The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.
摘要翻译： 本发明一般涉及表达人血液凝固因子如因子VIII，因子VII，因子IX和血管性血友病因子的非人转基因动物的开发。 本发明还提供使用所述转基因动物检测针对人血液凝固因子的免疫原性事件的方法。
-
公开(公告)号：US20110293598A1
公开(公告)日：2011-12-01
申请号：US13085056
申请日：2011-04-12
申请人： Leopold Bruckschwaiger , Sonja Svatos , Julia Nürnberger , Wolfgang Teschner , Harald Arno Butterweck , Hans-Peter Schwarz , Thomas Gundinger , Bernhard Koelbl , Reinhard Grausenburger , Azra Pljevljakovic
发明人： Leopold Bruckschwaiger , Sonja Svatos , Julia Nürnberger , Wolfgang Teschner , Harald Arno Butterweck , Hans-Peter Schwarz , Thomas Gundinger , Bernhard Koelbl , Reinhard Grausenburger , Azra Pljevljakovic
IPC分类号： A61K39/395 , A61P31/00 , A61P37/00 , C07K16/00 , A61P37/04
摘要： The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
-
公开(公告)号：US20110229455A1
公开(公告)日：2011-09-22
申请号：US12887424
申请日：2010-09-21
CPC分类号： A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
摘要： The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
摘要翻译： 本发明涉及具有增强或期望性质的ADAMTS13制剂。 因此，本发明提供了适用于药物给药的ADAMTS13的液体和冻干制剂。 除了其它方面，本发明还提供了治疗受试者中与VWF和/或ADAMTS13功能障碍相关的各种疾病和病症的方法。 本文还提供了包含可用于治疗各种疾病和病症的ADAMTS13制剂的试剂盒。
-
公开(公告)号：US20110021432A1
公开(公告)日：2011-01-27
申请号：US12842944
申请日：2010-07-23
申请人： Shawn F. BAIRSTOW , Richard J. Johnson , Sindhu Ramachandran , Ruth Madlener , Wolfgang Teschner , Hans-Peter Schwarz
发明人： Shawn F. BAIRSTOW , Richard J. Johnson , Sindhu Ramachandran , Ruth Madlener , Wolfgang Teschner , Hans-Peter Schwarz
CPC分类号： C07K14/472 , A61K38/1709 , A61K38/1725 , C07K1/36
摘要： The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction.
摘要翻译： 本发明提供衍生自血浆的因子H的组合物和药物制剂。 还提供了用于制备因子H组合物和制剂的方法，以及用于治疗与因子H功能障碍相关的疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
113 条记录 (耗时 0.062 秒)
